Abstract. Neoadjuvant treatment options for human epidermal growth factor receptor-2 (HER-2)-enriched and luminal B molecular subtypes of clinical breast cancer include HER-2-targeted therapy with chemotherapy or anti-hormonal therapy. These treatment options result in systemic toxicity and acquired tumor resistance. Minimally toxic naturally occurring phytochemicals may represent testable alternatives to conventional therapy. HER-2-overexpressing tumorigenic human mammary epithelial 184-B5/HER cells represent a model for the HER-2-enriched breast cancer subtype. Non-fractionated rosemary extract (RME) and constituent phenolic terpenoids ursolic acid (UA), carnosol (CSOL) and carnosic acid (CA) represented the test agents. Anchorage-independent (AI) proliferation, cell cycle progression, cellular apoptosis and expression of cell cycle-regulatory and apoptosis-specific proteins represented the mechanistic end point biomarkers. Relative to the parental non-tumorigenic 184-B5 cells, tumorigenic 184-B5/HER cells exhibited decreased population doubling, increased saturation density, accelerated cell cycle progression and downregulated cellular apoptosis, confirming the loss of homeostatic control of proliferation. Treatment with the test agents resulted in a dose-dependent decrease in AI colony number, indicating a decrease in cancer risk. Mechanistically, RME and UA inhibited G1-S phase transition resulting in an increased G1:S+G2/M ratio and decreased cyclin D1 expression. The pro-apoptotic effect of RME and UA was indicated by increased sub-G1 (apoptotic) cell population, and relevant reciprocal modulation, as demonstrated by decreased anti-apoptotic B-cell lymphoma-2 (Bcl-2) and increased pro-apoptotic Bcl-2-associated X protein expression. In contrast, treatment with CA and CSOL resulted in cytostatic G2/M arrest and an increase in cyclin B1 expression; thus, naturally-occurring rosemary and its constitutive terpenoids re-establish homeostatic control of proliferation and decrease cancer risk via distinct mechanisms. These data validate an experimental approach to prioritize efficacious natural compounds as testable alternatives for conventional chemo-endocrine and HER-2-targeted therapies in HER-2-enriched breast cancer.

Introduction

Genetically defined molecular subtypes of clinical breast cancer facilitate the accurate prediction of disease progression and rational selection of targeted therapeutic options. Expression of human epidermal growth factor receptor-2 (HER-2) on a background of estrogen receptor-α (ERα) and progesterone receptor (PR) positivity or negativity dictates distinct therapeutic options. These options are frequently associated with systemic toxicity, acquired tumor resistance and emergence of drug-resistant cancer stem cells favoring progression of therapy-resistant disease (1).

Targeted expression of HER-2, Ras and Myc oncogenes confers tumorigenic transformation in mammary epithelial cells (2-4). In the clinic, amplification of HER-2 in the presence of ERα and PR expression (luminal B subtype) or in the absence of their expression (HER-2-enriched subtype) dictate distinct therapeutic options, including antibody and/or small-molecule inhibitor-based HER-2-targeted therapy with or without hormone receptor- and/or aromatase inhibitor-based endocrine therapy (5-7).

Naturally occurring phytochemicals and herbal extracts that exhibit minimal systemic toxicity may represent testable alternatives to conventional chemo-endocrine therapy for treating breast cancer in the clinic (8,9). Published evidence on a model for HER-2-enriched breast cancer has demonstrated potent anti-proliferative and pro-apoptotic effects of a number of mechanistically distinct naturally occurring compounds, including phytoalexins (10), isoflavones (11,12), vitamin A derivatives (13) and phenolic terpenoids (14,15).

Rosemary (Rosmarinus officinalis L.) is a herb that is frequently used as a dietary spice and also exhibits medicinal properties. Rosemary and its constituent terpenoids are potent anti-inflammatory agents that inhibit chronic dermal inflammation, and skin tumor initiation and promotion (16,17); however, there is limited knowledge regarding the effects of rosemary...
and its constituent terpenoids in breast cancer, where expression of HER-2 oncogene has a negative effect on endocrine therapy.

The present study utilized a cellular model of human mammary epithelial cells that were tumorigenic owing to targeted expression of the HER-2 oncogene. These tumorigenic cells lack the expression of ERs and PRs, thus the expression of HER-2 on ERα- and PR-negative background provides a model for HER-2-enriched breast cancer. Experiments in the present study were designed to: i) Characterize the model at cellular and molecular level; ii) examine the proliferation inhibitory effects of rosemary and its constituent phenolic terpenoids; and iii) identify potential molecular mechanisms responsible for proliferation inhibitory efficacy.

Materials and methods

Cell lines. 184-B5 is a triple negative human mammary epithelial cell line that lacks the expression of ERα, PR and HER-2, and is non-tumorigenic (18). 184-B5/HER is a cell line derived from parental 184-B5 cells that are stably transfected with the HER-2 oncogene. These HER-2-expressing cells exhibit tumorigenic transformation (19). The two cell lines were obtained from Professor Clifford W. Welsch (Michigan State University, East Lansing, MI, USA). These cell lines were grown in Dulbecco's modified Eagle's medium: Nutrient mixture F12 (DME-F12; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10 ng/ml epidermal growth factor, 0.5 μg/ml hydrocortisone, 10 μg/ml transferrin, 10 μg/ml insulin and 5 μg/ml gentamicin (all from Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The 184-B5/HER cells were routinely maintained in the presence of 200 μg/ml G418 (Geneticin®; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The 184-B5 and 184-B5/HER cells were co-cultured at 80% confluency.

Test agents. Non-fractionated extract from rosemary leaves (RME) and carnosic (CSOL; molecular mass 330.42 Da) were provided by Nestlé Research Center (Lausanne, Switzerland). Ursolic acid (UA; molecular mass 456.70 Da) and carnosic acid (CA; molecular mass 332.43 Da) were purchased from Sigma-Aldrich; Merck KGaA. RME contained 20-30% UA, 15-20% CSOL and 10-15% CA. The stock solution of RME was prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck KGaA) at a concentration of 10 mg/ml. The stock solutions of UA, CA and CSOL were prepared in DMSO at concentrations of 10 mM. These stock solutions were serially diluted in DMEM-F12 culture medium to obtain final concentrations of 2, 5 and 10 μg/ml RME; 1, 5 and 10 μM UA and CA; and 1, 2.5 and 5.0 μM CSOL. These final concentrations were used for dose-response experiments on 184-B5/HER cells to identify the half-maximal inhibitory concentration (IC_{50}) and the maximum effective inhibitory concentration (IC_{90}).

Antibodies. The human reactive fluorescein isothiocyanate (FITC)-conjugated antibodies anti-B-cell lymphoma-2 (Bcl-2; cat. no. F7053) and anti-cyclin B1 (cat. no. F0169) were purchased from Dako; Agilent Technologies, Inc. (Santa Clara, CA, USA). Anti-human epidermal growth factor receptor-2 (HER-2; cat. no. SC7301), anti-epidermal growth factor receptor (EGFR; cat. no. SC101), anti-Bcl-2-associated X (Bax; cat. no. SC20067), anti-estrogen receptor-α (ER-α; cat. no. SC787) and anti-progesterone receptor (PR; cat. no. SC166169) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-cyclin D1 (cat. no. BDB554109) was purchased from BD Biosciences, Inc. (San Jose, CA, USA). These antibodies were used according to the recommended dilutions provided in the technical protocols from the suppliers in the present experiments to monitor the status of relevant proteins.

Proliferation assays. Population doubling times, saturation density, cell cycle progression and anchorage-independent (AI) colony formation were determined for the aforementioned cell lines following previously published optimized protocols (11,13). Population doubling times were determined from independent 24 h viable cell counts during the exponential phase for 4 days. Saturation density was determined from viable cell counts at day 7 post-feeding of 1x10^6 cells. The viable cell counts were determined by the trypan blue exclusion test using a hemocytometer. Cell cycle progression and cellular apoptosis were determined by flow-cytometer-based fluorescence-activated cell sorting using an EPICS 752 flow cytometer (Beckman Coulter, Inc., Miami, FL, USA). The data on distribution of the cell population in G1, S, G2/M and sub-G0 phases of the cell cycle was analyzed using the multi-cycle MPLUS software version 2.0 (Phoenix Flow Systems, San Diego, CA, USA), and the data are presented as the G1+S+G2/M phase ratio and the incidence of sub-G0 cell population. These data indicate the status of relative proportion of quiescent compared with proliferating cells, and the incidence of apoptotic cells. For the AI colony formation assay, 1,000 cells were suspended in 0.33% agar, overlaid on a basement matrix of 0.6% agar and maintained in culture for 21 days. The AI colony formation was then quantified by determining the number of colonies under an inverting light microscope at magnification, x10.

Cellular immunofluorescence assay. The cellular immunofluorescence was quantified in 184-B5 and 184-B5/HER cells stained with FITC-conjugated antibodies following the previously published optimized protocol (11,13). Briefly, the cell suspension was fixed in 0.25% paraformaldehyde (Polysciences, Inc., Warrington, PA, USA) made up in PBS (pH 7.4, Sigma-Aldrich; Merck KGaA, Darmstadt Germany) for 30 min on ice. The fixed cell suspension was subsequently incubated with 0.1% Triton X-100 (Sigma-Aldrich; Merck KGaA) on ice for 3 min to permeabilize the cell membrane. The permeabilized cells were washed twice with PBS (pH 7.4), and stained with the appropriate FITC-conjugated antibodies. Antibody stained 184-B5 and 184-B5/HER cells were monitored for antibody expression by fluorescence-activated cell sorting using a flow cytometer. Cells stained with isotype FITC-conjugated IgG represented the negative controls. The experimental data were corrected for FITC IgG and are presented as log mean fluorescence units (FU) per 1x10^5 fluorescence events.

Statistical analysis. Experiments for population doubling, saturation density, cell cycle progression and antibody-based immunofluorescence were performed in duplicate (n=6 per
ONCOLOGY LETTERS 16: 5489-5497, 2018

5491

Table I. Status of homeostatic control of proliferation and cancer risk in 184-B5/HER cells.

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>184-B5</th>
<th>184-B5/HER</th>
<th>Relative to 184-B5 cells (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population doubling</td>
<td>34.1±1.7 h</td>
<td>15.2±4.1 h</td>
<td>-55.4</td>
</tr>
<tr>
<td>Saturation density</td>
<td>23.7±1.3x10³</td>
<td>38.2±1.7x10³</td>
<td>+61.2</td>
</tr>
<tr>
<td>G₁:S+G₂/M ratio</td>
<td>1.8±0.3</td>
<td>0.8±0.1</td>
<td>-55.6</td>
</tr>
<tr>
<td>% Sub-G₀</td>
<td>18.9±2.6</td>
<td>0.6±0.2</td>
<td>-96.8</td>
</tr>
<tr>
<td>AI colony formation</td>
<td>0/18</td>
<td>18/18</td>
<td></td>
</tr>
<tr>
<td>Mean colony number</td>
<td>-</td>
<td>25.8±4.6</td>
<td></td>
</tr>
</tbody>
</table>

* Determined from cells in exponential phase. ** Determined from the viable cell number at day 7 post-seeding of 1.0x10⁶ cells. *** Determined from fluorescence-activated cell sorting. Results are presented as the mean ± SD, n=6 per biomarker. ** Determined at day 21 post-seeding of 1,000 cells. Results are presented as the mean ± SD, n=18 per treatment group. a P=0.04; b P=0.02 vs. 184-B5 cells. AI, anchorage-independent; SD, standard deviation.

Table II. Status of molecular markers in 184-B5/HER cells.

<table>
<thead>
<tr>
<th>Molecular marker</th>
<th>184-B5a</th>
<th>184-B5/HERa</th>
<th>Relative to 184-B5 cells (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERα</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>HER-2</td>
<td>0.3±0.1</td>
<td>53.8±2.5b</td>
<td>+17,830.0</td>
</tr>
<tr>
<td>EGFR</td>
<td>13.9±3.7</td>
<td>8.3±2.2</td>
<td>-40.3</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>62.2±5.7</td>
<td>80.5±5.1c</td>
<td>+29.4</td>
</tr>
<tr>
<td>Bax</td>
<td>59.8±3.3</td>
<td>26.6±2.7d</td>
<td>-55.5</td>
</tr>
</tbody>
</table>

* FITC-conjugated antibody-based cellular immunofluorescence. Results are presented as log mean FU ± standard deviation, n=6 per treatment group. Data corrected for FITC-conjugated IgG. ND, Non-detectable. Comparable FU in antibody-stained and IgG-stained cells. a P=0.01; b P=0.04; c P=0.03 vs. 184-B5 cells. ERα, estrogen receptor-α; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; EGFR, epidermal growth factor receptor; Bcl-2, B-cell lymphoma-2; Bax, Bcl-2 associated X protein; FITC, Fluorescein isothiocyanate; FU, fluorescence units.

treatment group). Experiments for AI colony formation were performed in triplicate (n=18 per treatment group). The data are presented as the mean ± standard deviation, and were analyzed for statistical significance between control and experimental groups using an unpaired two-sample Student's t-test using GraphPad Prism software (version 5.0; GraphPad Software, Inc., La Jolla, CA USA). P<0.05 was considered to indicate a statistically significant difference. Data comparing multiple treatment groups were analyzed by one-way analysis of variance and Dunnett's multiple range test, with a threshold of α=0.05.

Results

Proliferation characterization of the 184-B5/HER model. Experiments designed to examine the status of proliferation and cancer risk compared selected proliferation parameters in non-tumorigenic 184-B5 and tumorigenic 184-B5/HER cells (Table I). In comparison with 184-B5 cells, 184-B5/HER cells exhibited a 55.4% decrease (P=0.04) in population doubling time and a 61.2% increase (P=0.04) in saturation density. Additionally, these cells exhibited a 55.6% decrease (P=0.04) in the G₁:S+G₂/M ratio and a 96.8% decrease (P=0.02) in the sub-G₀ cell population. Furthermore, unlike 184-B5 cells, 184-B5/HER cells exhibited a high incidence of AI colony formation.

The data presented in Table II compare the status of selected cell-cycle-regulatory and apoptosis-specific gene products in 184-B5 and 184-B5/HER cells. The two cell lines lacked the expression of ERα and PR. Tumorigenic 184-B5/HER cells exhibited a 17.83% (178.3 fold) increase (P=0.01) in HER-2 expression. Additionally, the expression of anti-apoptotic Bcl-2 was increased by 29.4% (P=0.04), whereas pro-apoptotic Bax was decreased by 55.5% (P=0.03).

Effects of RME and constituent terpenoids on AI colony formation. Data from experiments designed to examine the effect of RME, CA, CSOL and UA on AI colony formation in 184-B5/HER cells are presented in Table III. A 21-day treatment with these agents resulted in a dose-dependent decrease in the number of AI colonies. The rank order of inhibitory efficacy at IC₅₀ concentration (α=0.05) for individual agents was CSOL > CA > RME > UA.

Inhibition of cell cycle progression. Data from experiments designed to examine the effect of RME and UA on the cell cycle progression of 184-B5/HER cells are presented in Fig. 1A and B. Relative to the G₁:S+G₂/M ratio of 1.2±0.3 in response to treatment with DMSO, treatment with RME and UA demonstrated a ratio of 2.8±0.7 (P=0.02) and 1.7±0.4 (P=0.04), respectively; thus, a 24 h treatment with high doses of RME and UA induced a 1.3-fold increase and a 41.7% increase in the G₁:S+G₂/M ratio, respectively (Fig. 1A). Relative to cyclin D1 expression of 14.7±2.1 FU in DMSO-treated cells, treatment with RME and UA exhibited FU values of 4.6±1.2...
Table III. Inhibition of AI colony formation in 184-B5/HER cells.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Concentration</th>
<th>Number of AI coloniesa</th>
<th>Inhibition (% solvent control)</th>
<th>IC₅₀</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td>0.1%</td>
<td>28.3±6.6b</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>RME</td>
<td>2 µg/ml</td>
<td>20.5±5.2</td>
<td>27.6</td>
<td>4.6</td>
</tr>
<tr>
<td></td>
<td>5 µg/ml</td>
<td>12.8±3.2b</td>
<td>54.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 µg/ml</td>
<td>2.6±0.6</td>
<td>91.8</td>
<td></td>
</tr>
<tr>
<td>UA</td>
<td>1 Mm</td>
<td>22.1±5.6</td>
<td>21.6</td>
<td>4.9</td>
</tr>
<tr>
<td></td>
<td>5 µM</td>
<td>13.9±3.4c</td>
<td>50.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 µM</td>
<td>2.8±0.6</td>
<td>90.1</td>
<td></td>
</tr>
<tr>
<td>CA</td>
<td>1 µM</td>
<td>18.4±4.6</td>
<td>34.9</td>
<td>4.2</td>
</tr>
<tr>
<td></td>
<td>5 µM</td>
<td>11.5±2.9d</td>
<td>59.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 µM</td>
<td>2.3±0.5</td>
<td>93.6</td>
<td></td>
</tr>
<tr>
<td>CSOL</td>
<td>1 µM</td>
<td>22.6±5.7</td>
<td>20.1</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>2.5 µM</td>
<td>14.1±3.5e</td>
<td>50.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5.0 µM</td>
<td>2.8±0.6</td>
<td>90.1</td>
<td></td>
</tr>
</tbody>
</table>

Results are presented as number of AI colonies mean ± standard deviation, n=18 per treatment group. a=P<0.05. b=Determined at day 21 post-seeding of 1,000 cells. c,DMSO > RME, α=0.05. d,DMSO > UA, α=0.05. e,DMSO > CA, α=0.05. f,DMSO > CSOL, α=0.05. Data were analyzed by one-way analysis of variance and Dunnett’s multiple range test (α=0.05). AI, anchorage-independent; DMSO, dimethyl sulfoxide; RME, rosemary extract; UA, ursolic acid; CA, carnosic acid; CSOL, carnosol; IC₅₀, half maximal inhibitory concentration.

(P=0.03), and 2.2±0.6 (P=0.03), respectively; thus, G₁ phase arrest induced by RME and UA was associated with a 68.7% decrease and an 85% decrease in G₁-specific cyclin D1 expression, respectively (Fig. 1B).

Induction of cellular apoptosis. Data from experiments designed to examine the effect of RME and UA on cellular apoptosis are presented in Fig. 2A and B. Relative to the sub-G₁ population of 0.6±0.3% in DMSO-treated cells, treatment with RME and UA demonstrated a sub-G₁ population of 6.3±1.6% (P=0.01) and 14.0±2.9% (P=0.01), respectively; thus, a 24 h treatment with RME and UA resulted in a 9.5- and 22.3-fold increase, respectively (Fig. 2A). Relative to the Bcl-2 expression of 69.2±5.7 FU in DMSO-treated cells, treatment with RME and UA demonstrated FU values of 41.5±1.8 (P=0.02) and 27.0±1.5 (P=0.02), respectively; thus, consistent with arrest of cells in the G₁/M phase of the cell cycle, CA- and CSOL-treated cells exhibited a 1.1-fold and 84.6% increase in the expression of the G₁-specific cyclin B1, respectively (Fig. 3B).

Regulation of cell cycle progression. The effects of CA and CSOL on cell cycle progression are presented in Fig. 3A and B. Relative to the G₁/M population of 17.5±2.6% in DMSO-treated cells, treatment with CA and CSOL demonstrated a G₁/M population of 40.0±1.7% (P=0.03) and 36.0±1.7% (P=0.03), respectively; thus, these treatments resulted in a 1.3-fold and a 1.0-fold increase of cell population in the G₁/M phase of the cell cycle (Fig. 3A). Relative to cyclin B1 expression of 13.0±3.7 FU in DMSO-treated cells, treatment with CA and CSOL demonstrated FU values of 27.0±1.5 (P=0.02) and 24.0±1.3 (P=0.02), respectively; thus, consistent with arrest of cells in the G₁/M phase of the cell cycle, CA- and CSOL-treated cells exhibited a 1.1-fold and 84.6% increase in the expression of the G₁-specific cyclin B1, respectively (Fig. 3B).

Discussion

The hormone receptor-positive, HER-2-expressing breast cancer (luminal B) molecular subtype is primarily treated using HER-2-targeted therapy and conventional endocrine therapy, including selective estrogen receptor modulators, selective estrogen receptor degraders and aromatase inhibitors. Hormone receptor-negative HER-2-expressing breast cancer is primarily treated with HER-2-targeted therapy and conventional chemotheraphy, including anthracyclines and taxanes. These long-term treatment options are associated with systemic toxicity and acquired tumor resistance that compromise treatment efficacy and favor drug-resistant disease progression (5-7,20). These limitations emphasize the importance of identifying novel, less toxic treatment options for chemo-endocrine therapy-resistant breast cancer. The present study utilized a cellular model for HER-2-enriched breast cancer to examine the proliferation inhibitory effects of RME and its constituent naturally occurring terpenoids, and to identify potential mechanisms of action for their efficacy.

Comparative experiments on non-tumorigenic 184-B5 cells and tumorigenic 184-B5/HER cells provided evidence that relative to 184-B5 cells, 184-B5/HER cells exhibited hyper-proliferation,accelerated cell cycle progression, downregulated cellular apoptosis and a high incidence of AI colony formation, the latter representing an in vitro surrogate endpoint marker for in vivo tumorigenic transformation. Notably, tumorigenic potential and AI colony formation have
been indicated to have a positive correlation for experimentally induced tumorigenic transformation in human mammary epithelial cells (2,19,21). Additionally, AI colony formation is detectable in cellular models for luminal A and triple negative molecular subtypes for clinical breast cancer (22,23). Collectively, these data provide evidence that AI colony formation represents an in vitro surrogate endpoint for tumorigenic transformation and an indicator for cancer risk; thus, these data indicate the loss of homeostatic control of proliferation and persistence of cancer risk. At the molecular level, 184-B5/HER cells exhibited modulated expression of HER-2 and EGFR. Furthermore, HER-2-expressing cells exhibited upregulation of anti-apoptotic Bcl-2 and downregulation of pro-apoptotic Bax. These molecular data may facilitate identification of potential targets for the proliferation inhibitory efficacy of novel anticancer compounds.

Experiments designed to examine the effects of RME and its constituent terpenoids CA, CSOL and UA on AI colony formation in 184-B5/HER cells indicated that these agents
decreased the number of AI colonies in a dose-dependent manner. This dose-response experiment identified individual IC$_{50}$ concentrations of the compounds and identified a rank order for the inhibitory efficacy of CSOL > CA > RME > UA.

The IC$_{50}$ non-toxic concentration of RME was identified to be 10 µg/ml. The maximum effective non-toxic concentrations for individual terpenoids were determined as 10 µM for UA, 10 µM for CA and 5 µM for CSOL. These concentrations contain 4.57 µg/ml UA, 3.32 µg/ml CA and 1.65 µg/ml CSOL, respectively; thus, a comparison of the concentrations (µg/ml) of RME and the three terpenoids indicates that the proliferation inhibitory efficacy of RME may be partially due to combined effects of these mechanistically distinct terpenoids, which are present in differing concentrations in RME.

Experiments designed to examine the effects RME and UA on cell cycle progression of 184-B5/HER cells demonstrated...
that RME, as well as UA, increased the G₁:S+G₂/M ratio and decreased cyclin D1 expression. These data indicated inhibition of cell cycle progression via inhibition of cyclin D1-dependent G₁ to S phase transition and resultant G₁ phase arrest. The pro-apoptotic effects of RME and UA in the present study were demonstrated by an increase of cell population in the sub-G₀ phase of the cell cycle, decreased expression of anti-apoptotic Bcl-2 and increased expression of pro-apoptotic Bax proteins.

Notably, RME terpenoids are effective in proliferation inhibition of cancer cells via multiple mechanistic pathways; thus, RME inhibits P-glycoprotein activity and reverses multi-drug resistance in hormone receptor-positive MCF-7 cells (24). Rosemary terpenoid UA has documented inhibitory efficacy against transcriptional activity of tumor promoter-inducible cyclooxygenase-2 (COX-2) via extracellular-signal-regulated kinases 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways in 184-B5/HER cells (14). In ERα-/PR-positive MCF-7 cells, proliferation inhibitory activity of UA is due to induction of apoptosis via the intrinsic mitochondrial pathway, involving the downregulation of Bcl-2 (25). Additionally, UA promotes the induction of autophagy, apoptosis, and anti-inflammatory responses via

![Figure 3. Regulation of cell cycle progression by CA and CSOL. (A) Treatment with CA and CSOL elicited an increase in G₂/M arrest. Results are presented as the mean ± SD, n=6 per treatment group. DMSO vs. CA, P=0.03; DMSO vs. CSOL, P=0.03. (B) Treatment with CA and CSOL resulted in an increase in the G₂ phase-specific cyclin B1 expression. Results are presented as the log mean FU ± SD, n=6 per treatment group. DMSO vs. CA, P=0.02; DMSO vs. CSOL, P=0.02. FU, fluorescence units; DMSO, dimethyl sulfoxide; CA, carnosic acid; CSOL, carnosol; SD, standard deviation.]
the suppression of phosphoinositide 3-kinase/protein kinase B and nuclear factor-kB pathways in a number of cellular models for breast cancer (26).

Experiments designed to examine the effects of CA and CSOL demonstrated that in comparison with RME and UA, these terpenoids induced G2/M phase arrest in 184-B5/HER cells and upregulated the expression of the G2 phase-specific cyclin B1. Consistent with the present results, published evidence has demonstrated that hydrophobic herbal flavonoids induce G2/M phase arrest and upregulated the expression of cyclin B1 in colorectal adenocarcinoma-derived HCT-116 and HT-29 cell lines (27). In the colorectal adenocarcinoma-derived Caco-2 cell line, CSOL and CA induce G2/M phase arrest via distinct modulation of increased cyclin B1 or decreased cyclin A levels (28). Furthermore, treatment of HER-2-expressing breast cancer cells with trastuzumab-entansine (T-DM1) conjugate upregulates cyclin B1 expression in T-DM1-sensitive, but not resistant, phenotypes (29); thus, high levels of cyclin B1 in G2/M arrested cells raise the possibility that proteasome-mediated degradation of the G2-specific cyclin may be impaired resultant to treatment with CA and CSOL. Furthermore, CA has been documented to synergize the antitumor activity of trastuzumab in HER-2-positive breast cancer cells (30), and CSOL has been identified to function as a potent inhibitor of transcriptional activation of inducible COX-2 and of prostaglandin production in 184-B5/HER cells. The mechanisms for efficacy of CSOL in this model involve protein kinase C, ERK1/2, JNK and p38-associated MAPK pathways (15). Collectively, the results of the present study provide evidence that the proliferation inhibitory efficacy of RME, UA, CA and CSOL is due to their selective effects on distinct phases of cell cycle progression and/or induction of cellular apoptosis via multiple context-dependent molecular mechanisms.

The results of the present study validate an experimental approach to identify clinically relevant mechanistic leads for efficacy of naturally occurring phytochemicals that may represent testable alternatives for treatment of HER-2-enriched breast cancer.

Acknowledgements

The author wishes to acknowledge active participation of Dr Hiromitsu Jinno from the Keio University School of Medicine, (Tokyo, Japan), Dr Melissa Steiner from the Weill-Cornell Medical College, (New York, NY, USA) and Dr Elizabeth Offord from the Nestlé Research Center, (Lausanne, Switzerland) in the research program entitled ‘Cellular models for molecular subtypes of clinical breast cancer: Mechanistic approaches for lead compound efficacy’.

Funding

The present study was supported by the US National Cancer Institute (NCI) FIRST Award (grant no. CA 44741), Program Project Grant (grant no. PO1-CA 29502), NCI Contract Research Master Agreement (grant no. CN 75029-63), Department of Defense Breast Cancer Research Program IDEA Award (grant no. DAMD-17-94-J-4208), and by philanthropic funds to Strang Cancer Prevention Center.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

The author contributed towards study conception, experimental design, data analysis, data interpretation, and prepared the manuscript for publication.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The author declares that there are no competing interests.

References


